Therefore, the purpose in this study was to clarify the molecular mechanism through which pemafibrate ameliorates the pathology of MASLD and to determine whether this effect depends on vascular endothelial function via the eNOS system. The gene discussed is NOS3; the disease is metabolic dysfunction-associated steatotic liver disease.